The Institute
The Centre for Genomic Regulation (CRG) is an international biomedical research institute of excellence, based in Barcelona, Spain, with more than 400 scientists from 44 countries. The CRG is composed of an interdisciplinary, motivated and creative scientific team supported by a flexible and efficient administration and high-end innovative technologies.
This is a Lab Technician position to study the role of X-chromosome inactivation for oocyte development in vitro from mouse embryonic stem cells. In a previous study (Severino et al., EMBO J 2022), we found evidence that X-inactivation is critical for meiotic and oogeneic potential. In this project, we want to test this directly and gain insight into the mechanism of this phenomenon. The role would be to assist in bringing this ongoing project to completion and publication.
This position will continue the work of Bernhard Payer's lab but will be incorporated into the Tissue Engineering facility.
About the lab
The Payer lab is interested in elucidating the mechanisms of epigenetic reprogramming during embryogenesis, in pluripotent stem cells, and in the germ cell lineage. One particular topic of our interest is the dramatic remodeling of the mammalian X chromosome in females from an inactive to an active state during a process called X-chromosome reactivation. We apply a multitude of in vivo and in vitro model systems, allowing us to interrogate this process and its link to pluripotency and germ cell development. The work environment at the CRG consists of a dynamic, international research institute in Barcelona (Spain), and English is the working language.
The Tissue Engineering Unit is a scientific-technological Core Technology within the Core Technologies Programme. The goal of the Tissue Engineering Unit is to provide CRG, PRBB, and external researchers with the latest technologies used in the fields of stem cell biology, stem cell differentiation, organoid formation, induced pluripotent stem cells (iPSCs), and CRISPR/Cas9 gene editing. It was created 8 years ago to help the research community perform Stem Cell and Organoids projects to increase the impact of Stem Cell and Organoid projects and applications. The Unit is constantly setting up new technologies that are emerging in the above fields.
Whom would we like to hire?
Professional experience
Must Have
Education and training
You hold a Master's in the Stem cell and epigenetics field.
Languages
You are fluent in English.
Technical skills
MS Office, Google Docs, Adobe Illustrator / Photoshop / Affinity designer or equivalent, R, Mammalian Cell culture.
Competences
Highly developed organizational skills.
The Offer – Working Conditions
Estimated annual gross salary: Salary is commensurate with qualifications and consistent with our pay scales.
We provide a highly stimulating environment with state-of-the-art infrastructures and unique professional career development opportunities. To check out our training and development portfolio, please visit our website in the training section.
We offer and promote a diverse and inclusive environment and welcome applicants regardless of age, disability, gender, nationality, ethnicity, religion, sexual orientation, or gender identity.
The CRG is committed to reconciling work and family life of its employees and offers an extended vacation period and the possibility to benefit from flexible working hours.
Application Procedure
All applications must include:
All applications must be addressed to Dr. Bernhard Payer and Dr. Laura Batlle and be submitted online through the "Apply" button below.
Selection Process
Pre-selection: The pre-selection process will be based on qualifications and expertise reflected in the candidates' CVs. It will be merit-based.
Interview: Preselected candidates will be interviewed by the Principal Investigator.
Offer Letter: Once the successful candidate is identified, the People department will send a Job Offer, specifying the start day, salary, working conditions, among other important details.
Deadline: Please submit your application by December 31, 2024.